Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 92
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves glycemic control in early-onset type 2 diabetes
Last updated July 4, 2026
Key finding
HbA1c decreased by -2.6% at week 40.
This study analyzed the effects of Tirzepatide on individuals with early-onset Type 2 diabetes, revealing significant improvements in various health markers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study analyzed the effects of Tirzepatide on individuals with early-onset Type 2 diabetes, revealing significant improvements in various health markers.
Clinical relevance
The findings highlight Tirzepatide's potential as a valuable treatment option for early-onset Type 2 diabetes, which is crucial for managing long-term health and preventing complications. Improved metabolic markers can lead to better overall health outcomes for patients.
Keep in mind
Effectiveness of Tirzepatide remains unclear due to limited evidence. Study results may not be generalizable to all populations. Sample size and duration may limit the robustness of findings.
Published in
Journal Reference
Publication details and source links for this paper.
Philip Z, Rodolfo JG, Melanie JD, et al. Post Hoc Analysis of Tirzepatide in Early-Onset Type 2 Diabetes: Baseline Characteristics and Treatment Effects. Diabetes Care. 2024;47(6):1056-1064. doi:10.2337/dc23-2356
Main Effects
HbA1c decreased by -2.6% at week 40.
Body weight decreased by -14 kg at week 40.
Waist circumference decreased by -10 cm at week 40.
Triglycerides decreased by -26% at week 40.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Diastolic blood pressure, Estimated glomerular filtration rate, and 7 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Diastolic blood pressure
- Estimated glomerular filtration rate
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
10
Evidence pairs
1373
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Fasting Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEstimated glomerular filtration rate
Tirzepatide → Estimated glomerular filtration rate
Tirzepatide → Estimated glomerular filtration rate
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 13 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- HbA1c levels decreased by -2.6%, indicating improved blood sugar control.
- Body weight reduction of -14 kg suggests significant weight loss benefits.
- Triglycerides decreased by -26%, reflecting improved lipid profiles.
Who this applies to
- Adults with early-onset Type 2 diabetes.
- Individuals seeking effective weight management strategies.
Keep in Mind
- Results may vary based on individual health conditions.
- Further research is needed to confirm long-term effects.
- The study's findings may not apply to older populations.
Between the Lines
- Effectiveness of Tirzepatide remains unclear due to limited evidence.
- Study results may not be generalizable to all populations.
- Sample size and duration may limit the robustness of findings.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 13 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 92
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
View evidenceMedications
GLP-1 Receptor Agonists → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
13 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
13 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
12 studies
outcome_hubMeasures Body Weight as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
2 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
13 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
12 results
All studies on Tirzepatide
Intervention: Tirzepatide
13 results
All studies measuring HbA1c
Outcome: HbA1c
13 results
All studies measuring Body weight
Outcome: Body weight
12 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.7 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 76.5 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve adipokine and angiogenic markers?
Strong Evidence
GLP-1 Receptor Agonists may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
- 2
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Structured exercise improves metabolic health in prediabetic adultsHigh-protein diet may reduce cardiometabolic risks in diabetes patientsHibiscus extract may improve kidney function in type 2 diabetesTime-restricted diet aids glucose control in diabetesInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.